Superluminal Medicines raised a $60 million oversubscribed Series B to advance its AI-powered GPCR platform and move its first clinical program into Phase I by year-end. The lead candidate is a selective, biased melanocortin-4 receptor (MC4R) agonist aimed at rare genetic and hypothalamic forms of obesity, targeting signaling specificity designed to reduce side effects. BVF Partners led the financing, with participation from Deep Track Capital and Perceptive Advisors and continued support from investors including RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. The company says the funding will support the program through early human testing and trial initiation. For the obesity drug market, the raise reinforces investor appetite for targeted, pathway-specified approaches beyond broad GLP-1 competition, particularly in genetically defined, underserved patient populations.